Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma

Trial Profile

A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-cell Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Bortezomib (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vindesine
  • Indications T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2007 Additional lead trial center and investigators identified as reported by ClinicalTrials.gov.
    • 06 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top